In this Article Investigational Agent Slows Brain Shrinkage in Progressive MS Gilenya® Reduces Relapse Rate in Pediatric MS When It Comes to Remembering, Togetherness Helps Recognizing the Frequency – and Addressing the Impact – of Swallowing Problems in MS How Impact on Quality of Life Differs by Type of MS More Sun Early in Life […]

In the event of a disaster in your area, make sure you can access emergency services.

The entire staff at the Multiple Sclerosis Association of America (MSAA), as well as many of MSAA’s corporate partners, are mourning the loss of our former Chief Operating Officer and treasured colleague, Robert “Bob” Rapp. Following a successful career in education and public service, Bob joined the staff of MSAA as Director of Services in […]

EMD Serono, Inc. announced today that the United States Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for Cladribine Tablets (an oral formulation of cladribine), an investigational treatment for relapsing forms of MS. Accepted by the European Commission in August 2017 and by Canada in December 2017, Cladribine is currently approved […]

In this Article Disease-Modifying Therapies in the Research Pipeline Long-Term Efficacy and Safety of Approved DMTs Comparative Analyses of Approved DMTs New Diagnostic Testing Various Strategies for Wellness and Symptom Management, Physical Activity and Exercise, Vitamin D, and Reproductive-Health Topics Hot Topics in MS: Stem Cells, Lipoic Acid, Diet and MS, Obesity and MS, Gut […]

My MS Manager™ is the Multiple Sclerosis Association of America’s mobile phone app designed to be a convenient and effective tool for members of the MS community to help manage their condition. The app, powered by @Point of Care, is available to download free of charge for both iOS and Android devices. Features available in […]

The MRI Access Fund assists with the payment of cranial (brain) and c-spine MRI scans for qualified individuals who have no medical insurance or cannot afford their insurance costs. The exam must be required by a physician to help determine a diagnosis of multiple sclerosis or evaluate current MS disease progression.